Clinical trials: Metastatic Nasopharyngeal Cancer
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00049283
- Testing
- erlotinib hydrochloride, docetaxel, radiation therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them.
- Trial name
- NCT00301028
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Head and Neck Cancer
Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for skin cancer and cancer that is metastatic to the skin.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer
- Trial name
- NCT00023790
- Testing
- silicon phthalocyanine 4
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Head and Neck Cancer
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00509665
- Testing
- doxorubicin hydrochloride, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Nasopharyngeal Carcinoma
To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC
- Trial name
- NCT04387266
- Testing
- modified reduce-volume target IMRT
- Where
- China
- Volunteers
- 471 people
- Sponsor
- Fujian Cancer Hospital
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Radiation Toxicity
- Trial name
- NCT00003251
- Testing
- amifostine trihydrate, cisplatin, paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Illinois Chicago
Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic…
- Trial name
- NCT06331845
- Testing
- Gemcitabine, Cisplatin, Paclitaxel protein-bound
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Toxicity Due to Radiotherapy, Nasopharyngeal Carcinoma
Clincal Study of Reduced Target Radiotherapy in Nasopharyngeal Carcinoma
To determine whether subtractive radiotherapy can significantly reduce the acute side effects of radiotherapy and improve the quality of life of patients on the basis of ensuring the existing curative effect.
- Trial name
- NCT05741008
- Testing
- Target range
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Kunming Medical University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
This randomized phase I/II trial studies the side effects and best way to give lyophilized black raspberries in preventing oral cancer in high-risk patients previously diagnosed with stage I-IV or in situ head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage 0 Hypopharyngeal Cancer, Stage 0 Laryngeal Cancer
- Trial name
- NCT01469429
- Testing
- laboratory biomarker analysis, questionnaire administration, chemoprevention
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Nasopharyngeal Carcinoma
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
The purpose of this randomized controlled Phase II study is to assess the efficacy of PDR001 versus investigator's choice of chemotherapy in patients with advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02605967
- Testing
- Spartalizumab, Investigator choice of chemotherapy
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Nasopharyngeal Carcinoma
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
This is a single-arm, open-label, multicenter, phase II study to evaluate the anti-tumor activity, PK and immunogenicity of AK104 in patients with metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior…
- Trial name
- NCT04220307
- Testing
- AK104
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Akeso
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
This phase I trial studies how well talactoferrin works in treating patients with relapsed or refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01528137
- Testing
- talactoferrin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Nasopharyngeal Neoplasms
The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients
A circulating tumor cell (CTC) count is an established prognostic factor in some malignancies such as metastatic breast cancer. However, the value of CTC in diagnosis and outcome prediction of metastatic nasopharyngeal carcinoma…
- Trial name
- NCT02505139
- Testing
- the number of circulating tumor cells
- Volunteers
- 166 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma
this study is aimed to evaluate the efficacy and safety of the combination of Niraparib and Sintilimab in the treatment of recurrent/metastatic nasopharyngeal carcinoma
- Trial name
- NCT05162872
- Testing
- Niraparib，Sintilimab
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Maintenance Therapy
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
The aim of this study is to investigate the efficacy and safety of the "capecitabine combined with toripalimab maintenance regimen" in improving the first-line treatment of recurrent and metastatic nasopharyngeal carcinoma after…
- Trial name
- NCT05869227
- Where
- China
- Volunteers
- 166 people
- Sponsor
- XIANG YANQUN
Nasopharyngeal Carcinoma
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and…
- Trial name
- NCT06383780
- Testing
- GP combined with Tislelizumab, TPC combined with Tislelizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- XIANG YANQUN
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center